Cohance Lifesciences Ltd
General updates
Cohance Lifesciences Ltd has received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
41
total announcements
COHANCE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹17,511 Cr
P/E (TTM)
167.7
P/E (Forward)
47.2
EPS (TTM)
₹2.73
52W Low
₹266.70
52W High
₹917.85
Dividend Yield
0.00%
Beta
0.62
Price / Book
4.5
Debt / Equity
9.9
Revenue (TTM)
₹2,142 Cr
Gross Margin
70.36%
Operating Margin
-11.46%
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has granted 8,74,788 stock options to eligible employees under the ESOP 2026 and ESOP 2023 schemes, with vesting periods ranging from 1 to 8 years and exercise periods up to 3 years.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has appointed a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
COHANCE LIFESCIENCES LIMITED
COHANCE LIFESCIENCES LIMITED has informed BSE about the appointment of a new Chief Financial Officer.
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has appointed Mr. Abhimanyu Ojha as its Chief Financial Officer, effective from 12 October 2026.
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30 September 2026, confirming the details of securities dematerialized/rematerialized during the period.
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has been assigned an ESG Rating of 'Crisil ESG 61 (Strong)' and Core ESG Rating of 'Crisil Core ESG 67 (Strong)' by Crisil ESG Ratings & Analytics Limited.
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives from 1 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending 30 September 2026.